Last Friday, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for Juta Pharma’s pegfilgrastim biosimilar, Grasustek.
Last Friday, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for Juta Pharma’s pegfilgrastim biosimilar, Grasustek.
The next step for the biosimilar will be to await the European Commission (EC)’s final decision on whether to grant a marketing approval for the biosimilar. If the EC ultimately approves the product, it will grant the company a centralized marketing authorization that will be valid in all 28 EU member states. Norway, Iceland, and Liechtenstein, members of the European Economic Area, will follow with corresponding decisions based on the EC’s decision.
If authorized, Grasustek will be available as a 6 mg solution for injection for the prophylaxis of neutropenia in adults being treated with cytotoxic chemotherapy.
The pegfilgrastim biosimilar was developed by USV, a Mumbai-based biosimilar developer that submitted the application for the biosimilar in December 2017. USV later acquired Juta Pharma, a German drug maker with extensive experience in generic drug products.
The application for the biosimilar included data from phase 1 and phase 3 studies of the biosimilar; the phase 1 study compared the pharmacokinetics and pharmacodynamics of the biosimilar with the reference Neulasta at both a therapeutic dose and a low dose, and the phase 3 study followed 254 patients with breast cancer who were scheduled to undergo chemotherapy.
USV also disclosed that it had begun planning for US phase 1 development, and held relevant meetings with the FDA. The company also received approval to initiate phase 3 studies in India.
If Grasustek is authorized in the European Union, it will join already authorized pegfilgrastim biosimilars Fulphila, Ziextenzo, Udenyca, Pelmeg, and Pelgraz. Additional EU-marketed biosimilars used in the prophylaxis of febrile neutropenia are those referencing filgrastim, and include Zarzio (also sold as Filgrastim Hexal), Accofil, Grastofil, Nivestim, and Ratiograstim (also sold as Tevagrastim).
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.